Credit rating agency, CARE has revised rating of Granules India’s long term bank facilities worth Rs 171.80 crore to ‘A-’ from ‘BBB+’. The rating agency has revised rating of company’s short term bank facilities worth Rs 388 crore to ‘A2+’ from ‘A2’.
The revision of ratings of Granules India (GIL) takes into account significant increase in scale of operations, profitability margins and improvement in debt coverage indicator during FY14 (refers to period April 1 to March 31). The ratings of GIL continues to draw strength from the experienced management, established track record with diversified presence across major global pharmaceuticals markets, reputed clientele, and positive demand outlook for the pharmaceutical sector.
Granules India is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1786.05 |
Dr. Reddys Lab | 1354.20 |
Cipla | 1470.05 |
Lupin | 2190.50 |
Zydus Lifesciences | 1004.05 |
View more.. |